Hosted by: Mark Hollmer, Editor, FierceBiotech Research
Join FierceBiotech on November 13th to learn how sequencing, genotyping, and informatics systems are changing the way cancer drugs are developed, from selecting patients in clinical trials, implementing adaptive trial designs and speeding programs through the clinic.
Richard Wooster, Vice President, Head of Cancer Metabolism Drug Discovery, Oncology R&D, GlaxoSmithKline Richard Wooster has a background in cancer genetics. He mapped and cloned the breast cancer susceptibility gene BRCA2 and was one of the 3 founders of the Cancer Genome Project at the Sanger Institute that discovered mutations in the BRAF gene. In 2006 Richard joined GlaxoSmithKline. He currently leads a multidisciplinary team focused on the discovery and develop medicines that target deregulated metabolic pathways in cancer cells.
Dan Paterson, VP, Head of Corporate Development and Diagnostics, Verastem Mr. Paterson has over 20 years of experience in management roles at healthcare and biotechnology companies, including as COO and CEO, and specific expertise in oncology drug and diagnostic product development. He was also the founding CEO of The DNA Repair Company (acquired by On-Q-ity) which develops oncology-focused molecular diagnostics. He has designed and managed clinical trials in both industry and academic settings and holds a B.A. in Biology from Boston University.
Anup Madan, Ph.D. , Senior Scientist, Genomics/Sequencing Group Lead, Covance Genomics Lab Anup Madan, Ph.D. is the Principal Scientist, Genomics/Associate Director, Sequencing Group at Covance. He is responsible for developing Next generation sequencing platform for providing sequence based assays as core services by Covance Genomic Laboratory and as well as developing novel MDx assays to support various clinical trials. Anup has a Ph.D. in Biochemical Genetics from Tata Institute of Fundamental Research in Mumbai , India .